<DOC>
	<DOCNO>NCT01475734</DOCNO>
	<brief_summary>This step glucose clamp study design investigate effect treatment albiglutide counter-regulatory hormone response recovery hypoglycemia subject Type 2 diabetes mellitus . A single dose albiglutide placebo give prior step hyper- hypoglycemic clamp . The goal study demonstrate albiglutide increase insulin secretion decrease glucagon level glucose-dependent manner .</brief_summary>
	<brief_title>Albiglutide Glucose Clamp Study Subjects With Type 2 Diabetes</brief_title>
	<detailed_description>This Phase II , single-site , randomize , double-blind , parallel-group , placebo-controlled , step glucose clamp study design investigate effect treatment albiglutide counter-regulatory hormone response recovery hypoglycemia subject Type 2 diabetes mellitus . A single dose albiglutide placebo give 3 day employ step hyper- hypoglycemic clamp . The goal study demonstrate albiglutide increase insulin secretion decrease glucagon level glucose-dependent manner . In particular , study conduct ensure albiglutide impair counter-regulatory response hypoglycemia .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Historical diagnosis type 2 diabetes mellitus least 6 month le 10 year Screening HbA1c &lt; 10 % Screening subject require washout exist OAD &lt; 9 % Screening subject require washout exist OAD Body mass index range 28 kg/m2 to40 kg/m2 History pancreatitis current ongoing symptomatic biliary disease pancreatitis History significant gastrointestinal surgery , History significant cardiovascular disease History seizure disorder Documented hypertension hypotension Use oral antidiabetic agent , except metformin , within 14 day investigational product administration . Current hepatic disease abnormal liver function test Positive test result hepatitis B , hepatitis C , human immunodeficiency virus infection 1 2 History regular alcohol consumption ( exceed 7 drinks/week woman 14 drinks/week men ) Female subject pregnant ( confirmed laboratory test ) , lactate , less 6 week postpartum Known allergy GLP1 analog excipients albiglutide , Baker 's yeast , insulin History type 1 diabetes , Prior exposure GLP1 agent , include albiglutide Blood donation 500 mL within 8 week Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>glucose clamp</keyword>
	<keyword>hypoglycemia</keyword>
</DOC>